Lv1
92 积分 2020-12-04 加入
Phase 1 Radioimmunotherapy Study with Lutetium 177–labeled Anti-Carbonic Anhydrase IX Monoclonal Antibody Girentuximab in Patients with Advanced Renal Cell Carcinoma
2天前
已完结
A phase 1 trial to determine the maximum tolerated dose and patient-specific dosimetry of [177Lu]Lu-LNC1003 in patients with metastatic castration-resistant prostate cancer
2天前
已完结
An Overview of Gene Editing Modalities and Related Non-clinical Testing Considerations
12天前
已完结
Non-Clinical Safety Assessment of Novel Drug Modalities: Genome Safety Perspectives on Viral-, Nuclease- and Nucleotide-based Gene Therapies
12天前
已完结
A new age of precision gene therapy
12天前
已完结
Targeted protein degradation: from mechanisms to clinic
18天前
已完结
Synthesis, preclinical evaluation and pilot clinical translation of [68Ga]Ga-PMD22, a novel nanobody PET probe targeting CLDN18.2 of gastrointestinal cancer
28天前
已完结
Claudin-18.2 attracts the cancer crowd
1个月前
已完结
Claudin 18.2 as a novel therapeutic target
1个月前
已完结
Current understanding of CREPT and p15RS, carboxy-terminal domain (CTD)-interacting proteins, in human cancers
1个月前
已完结
皖公网安备34019202002308
